Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)?
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
Our hypothesis is that the medication approved for treatment of high blood cholesterol
levels, Colesevelam HCl (WELCHOL), decreases colonic transit and permeability in patients
with diarrhea due to irritable bowel syndrome.
This effect is thought to result from the effect of the medication on bile acids, which can
cause diarrhea.
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)